Supernus Pharmaceuticals (SUPN -4.7%) slips on below-average volume on the heels of a note from Piper Jaffray’s David Amsellem (Neutral/$47) stating that the results from an in-house survey of 25 neurologists suggested weakening volume growth for top seller Trokendi XR which accounted for 77% of the company’s 2017 product sales ($226.5M/294.1M).
Mr. Amsellem adds that the significance of the pressure on volume/sales growth is “unclear” but he believes Trokendi XR will not be a significant revenue growth drive in the coming years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.